TY  - JOUR
AU  - Powles, Thomas
AU  - Kockx, Mark
AU  - Rodriguez-Vida, Alejo
AU  - Duran, Ignacio
AU  - Crabb, Simon J
AU  - Van-Der-Heijden, Michiel S
AU  - Szabados, Bernadett
AU  - Pous, Albert Font
AU  - Gravis, Gwenaelle
AU  - Herranz, Urbano Anido
AU  - Protheroe, Andrew
AU  - Ravaud, Alain
AU  - Maillet, Denis
AU  - Mendez, Maria Jose
AU  - Suarez, Cristina
AU  - Linch, Mark
AU  - Prendergast, Aaron
AU  - van-Dam, Pieter-Jan
AU  - Stanoeva, Diana
AU  - Daelemans, Sofie
AU  - Mariathasan, Sanjeev
AU  - Tea, Joy S
AU  - Mousa, Kelly
AU  - Banchereau, Romain
AU  - Castellano, Daniel
PY  - 2019
DO  - 10.1038/s41591-019-0628-7
UR  - http://hdl.handle.net/10668/14633
T2  - Nature medicine
AB  - Antibodies targeting PD-1 or its ligand 1 PD-L1 such as atezolizumab, have great efficacy in a proportion of metastatic urothelial cancers1,2. Biomarkers may facilitate identification of these responding tumors3. Neoadjuvant use of these agents is...
LA  - en
PB  - Nature Publishing Group
KW  - Predictive markers
KW  - Bladder cancer
KW  - Aged
KW  - Antibodies, Monoclonal, Humanized
KW  - Biomarkers, Tumor
KW  - Carcinoma, Transitional Cell
KW  - DNA Repair
KW  - Disease-Free Survival
KW  - Female
KW  - Gene Expression Regulation, Neoplastic
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Neoadjuvant Therapy
KW  - Neoplasm Invasiveness
KW  - Transcriptome
KW  - Transforming Growth Factor beta
KW  - Urologic Neoplasms
KW  - Urothelium
TI  - Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.
TY  - research article
VL  - 25
ER  -